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Disruption of PTPRO Causes Childhood-Onset
Nephrotic Syndrome
Fatih Ozaltin,1,2,* Tulin Ibsirlioglu,2 Ekim Z. Taskiran,3 Dilek Ertoy Baydar,4 Figen Kaymaz,5
Mithat Buyukcelik,6 Beltinge Demircioglu Kilic,6 Ayse Balat,6 Paraskevas Iatropoulos,7 Esin Asan,5
Nurten A. Akarsu,8 Franz Schaefer,9 Engin Yilmaz,3 Aysxin Bakkaloglu,1 and the PodoNet Consortium10
Idiopathic nephrotic syndrome (INS) is a genetically heterogeneous group of disorders characterized by proteinuria, hypoalbuminemia,
and edema. Because it typically results in end-stage kidney disease, the steroid-resistant subtype (SRNS) of INS is especially important
when it occurs in children. The present study included 29 affected and 22 normal individuals from 17 SRNS families; genome-wide anal-
ysis was performed with Affymetrix 250K SNP arrays followed by homozygosity mapping. A large homozygous stretch on chromosomal
region 12p12was identified in one consanguineous family with two affected siblings. Direct sequencing of protein tyrosine phosphatase
receptor type O (PTPRO; also known as glomerular epithelial protein-1 [GLEPP1]) showed homozygous c.2627þ1G>T donor splice-site
mutation. This mutation causes skipping of the evolutionarily conserved exon 16 (p.Glu854_Trp876del) at the RNA level. Immunohis-
tochemistry with GLEPP1 antibody showed a similar staining pattern in the podocytes of the diseased and control kidney tissues. We
used a highly polymorphic intragenic DNA marker—D12S1303—to search for homozygosity in 120 Turkish and 13 non-Turkish indi-
viduals in the PodoNet registry. This analysis yielded 17 candidate families, and a distinct homozygous c.2745þ1G>A donor splice-site
mutation in PTPROwas further identified via DNA sequencing in a second Turkish family. Thismutation causes skipping of exon 19, and
this introduces a premature stop codon at the very beginning of exon 20 (p.Asn888Lysfs*3) and causes degradation of mRNA via
nonsense-mediated decay. Immunohistochemical analysis showed complete absence of immunoreactive PTPRO. Ultrastructural alter-
ations, such as diffuse foot process fusion and extensivemicrovillus transformation of podocytes, were observed via electronmicroscopy
in both families. The present study introduces mutations in PTPRO as another cause of autosomal-recessive nephrotic syndrome.Idiopathic nephrotic syndrome (INS), a disorder character-
ized bymassive proteinuria due to loss of glomerular perm-
selectivity resulting from podocyte functional alterations,
affects 16 children out of 100,000.1 Whereas in the
majority of cases the disorder is caused by immunological
alterations readily responsive to glucocorticoid treatment,
and individuals have an excellent long-term prognosis,
10%–20% of individuals are steroid resistant (SRNS) and
typically progress to end-stage kidney disease (ESKD).2 In
recent years, inherited defects in podocyte structure and
function were observed in a fraction of children with the
steroid-resistant subtype (SRNS). To date, abnormalities
in seven genes expressed in the podocyte have been re-
ported to cause nonsyndromic SRNS in humans.3–9
LAMB2 (MIM 150325) mutations cause Pierson syn-
drome (MIM 609049), which is characterized by congen-
ital nephrotic syndrome with distinct eye abnormali-
ties.10 Mutations in exons 8 and 9 of WT1 (MIM 607102)
have been observed in individuals with isolated SRNS
and in those with SRNS associated with Wilms’ tumor or
urogenital malformations (i.e., Denys-Drash syndrome
[DDS] [MIM 194080] and Frasier syndrome [MIM
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The Amapproximately 15%–20% of SRNS cases, suggestingmarked
genetic heterogeneity of the disorder.
In the present study, we performed genome-wide anal-
ysis followed by homozygosity mapping to identify
mutations in additional genes in a large cohort of SRNS
individuals. The study included 17 autosomal-recessive
SRNS families, defined according to standard criteria.12
Mutations in NPHS2 (MIM 604766) and WT1 (MIM
607102) in all cases and in NPHS1 (MIM 602716), LAMB2
(MIM 150325), and PLCE1 (MIM 608414) in cases with
congenital nephrotic syndrome were ruled out via direct
sequencing. In all, 29 affected and 22 normal individuals
from the 17 families were included in the genome-wide
analysis, which was performed with GeneChip mapping
250K NspI SNP arrays from Affymetrix according to the
manufacturer’s recommendations. Genotype files (CHP
files) were generated with Affymetrix GTYPE software
and were transferred to the VIGENOS (Visual Genome
Studio) program (Hemosoft, Ankara), which facilitates
visualization of a large quantity of genomic data in
comprehensible visual screens.13
In affected cases, large homozygous segments overlap-
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Figure 1. Positional Cloning of PTPRO
Mutations in Family A
(A) The pedigree of the index family.
Squares indicate males and circles indicate
females. Solid symbols indicate affected
individuals. Double-horizontal bars indi-
cate consanguinity.
(B) The schematic representation of
homozygosity data. Genotype files (CHP
files) were generated with Affymetrix
GTYPE software and were transferred to
the VIGENOS (Visual Genome Studio)
program (Hemosoft, Ankara),13 which
facilitates visualization of a large quantity
of genomic data in comprehensible visual
screens. Homozygous genotypes identical
to the genotype data obtained from the
index case (IV-1) are shown in blue. Con-
trasting homozygote genotypes are shown
in white, whereas heterozygous SNPs
appear in orange. Noninformativeness as
a result of heterozygous genotypes in
parent-child trios is indicated in yellow.
No calls are indicated in gray. The overlap-
ping homozygous stretches in two
affected individuals are approximately 14
Mb in size between markers rs16928082
and rs10841414 on chromosome 12.
(C–E) The sequence electropherograms of
exon 16 of PTPRO. Thewild-type sequence
in a healthy control is shown in the left
electropherogram (C, arrow). Whereas the
healthy parents were heterozygous for
the mutation (D, arrow), both affected
siblings had a homozygous donor splice-
site c.2627þ1G>T (p.Glu854_Trp876del)
mutation (E, arrow); dashed blue lines
show exon-intron boundaries.
(F) The position of the mutation is shown
as red in the genomic sequence.Horizontal
arrows indicate subsequent introns and
exons. Vertical arrows show intron-exon
boundaries. Four-digit numbers (i.e., 2559
and2627) show starting and endingnucle-
otides of exon 16.
(G) Sequencing of PTPRO cDNA of both
peripheral blood lymphoctes fromhealthy
individuals and nephrectomy specimens
showed that exon 15 was followed by
exon 16 (normal splicing). Dashed line
shows exon-exon boundaries.
(H–J) c.2627þ1G>T donor splice-site
mutation (NM_002848.2) in Family A
results in skipping of exon 16, which is
conserved during evolution (see also
Figure S3). Four-digit numbers show start
and end positions of the respective exons.analysis, which did not show any shared regions of homo-
zygosity among the 17 families, indicated extensive
genetic heterogeneity of nephrotic syndrome. Each family
was then individually analyzed; overlapping homozygous
haplotype stretches in affected family members were re-
corded, and functional candidate genes positioned in these
regions were identified. This approach showed that there
was one consanguineous family (family A, Figures 1A
and 1B) that contained two affected siblings and a large140 The American Journal of Human Genetics 89, 139–147, July 15, 2homozygous stretch spanning approximately 14 Mb
between markers rs16928082 (SNP_A-2293685) and
rs10841414 (SNP_A-2047221) on chromosome 12. This
region harbored 182 genes. In this particular family, four
additional loci on chromosomal regions 8qtel, 11p15,
17ptel, and 18q11 (Figure S1, available online) were also
observed; however, the chromosomal region 12pwas high-
lighted because of the presence of a highly relevant candi-
date gene—protein tyrosine phosphatase receptor type O011
T
a
b
le
1
.
C
li
n
ic
a
l
F
e
a
tu
re
s
o
f
th
e
A
ff
e
c
te
d
In
d
iv
id
u
a
ls
w
it
h
P
T
P
R
O
M
u
ta
ti
o
n
s
F
a
m
il
y
a
n
d
In
d
iv
id
u
a
l
C
o
n
sa
n
g
u
in
it
y
N
u
c
le
o
ti
d
e
A
lt
e
ra
ti
o
n
a
S
e
g
re
g
a
ti
o
n
A
g
e
a
t
O
n
se
t
(y
e
a
rs
)
In
it
ia
l
U
p
/
U
c
(m
g
/
m
g
)
S
e
ru
m
A
lb
u
m
in
a
t
O
n
se
t
(g
d
L

1
)
A
g
e
a
t
E
S
K
D
(y
e
a
rs
)
H
is
to
lo
g
y
L
a
st
U
p
/
U
c
(m
g
/
m
g
)
L
a
st
se
ru
m
a
lb
u
m
in
(g
d
L

1
)
A IV
-1
y
es
c.
2
6
2
7
þ1
G
>
T
H
,
M
,
P
7
9
.9
2
.5
n
o
n
e
at
1
1
y
ea
rs
N
D
3
.8
4
IV
-2
y
es
c.
2
6
2
7
þ1
G
>
T
H
,
M
,
P
5
1
6
.2
1
.9
n
o
n
e
at
7
y
ea
rs
F
SG
S
1
.1
8
3
.6
B IV
-1
y
es
c.
2
7
4
5
þ1
G
>
A
H
,
M
,
P
1
4
1
4
.1
2
.2
1
8
(t
ra
n
sp
la
n
te
d
)
N
D
0
.1
2
4
IV
-2
y
es
c.
2
7
4
5
þ1
G
>
A
H
,
M
,
P
1
1
7
4
n
o
n
e
at
1
5
y
ea
rs
M
C
D
3
.2
4
.2
IV
-3
y
es
c.
2
7
4
5
þ1
G
>
A
H
,
M
,
P
9
6
.1
4
n
o
n
e
at
1
2
y
ea
rs
N
D
2
.9
3
.6
IV
-4
y
es
W
T
h
ea
lt
h
y
0
.1
T
h
e
fo
llo
w
in
g
a
b
b
re
vi
a
ti
o
n
s
a
re
u
se
d
:
W
T
,
w
ild
-t
y
p
e
;
H
,
H
o
m
o
zy
g
o
u
s
in
a
ff
e
ct
e
d
in
d
iv
id
u
a
l;
M
,
h
e
te
ro
zy
g
o
u
s
m
u
ta
ti
o
n
id
e
n
ti
fi
e
d
in
m
o
th
e
r;
P
,
h
e
te
ro
zy
g
o
u
s
m
u
ta
ti
o
n
id
e
n
ti
fi
e
d
in
fa
th
e
r;
U
p
/U
c:
u
ri
n
a
ry
p
ro
te
in
/c
re
a
ti
n
in
e
ra
ti
o
;
FS
G
S
:
Fo
ca
l
se
g
m
e
n
ta
l
g
lo
m
e
ru
lo
sc
le
ro
si
s;
M
C
D
;
m
in
im
a
l
ch
a
n
g
e
d
is
e
a
se
;
N
D
:
n
o
t
d
o
n
e
.
E
S
K
D
:
E
n
d
-s
ta
g
e
ki
d
n
e
y
d
is
e
a
se
.
a
T
h
e
n
u
cl
e
o
ti
d
e
p
o
si
ti
o
n
s
a
re
n
u
m
b
e
re
d
a
cc
o
rd
in
g
to
va
ri
a
n
t
2
o
f
P
T
P
R
O
(N
M
_
0
0
2
8
4
8
.2
).
A
ll
m
u
ta
ti
o
n
s
w
e
re
a
b
se
n
t
in
1
8
0
h
e
a
lt
h
y
T
u
rk
is
h
ch
ild
re
n
.(PTPRO), also known as GLEPP1 (glomerular epithelial
protein-1) (MIM 600579).
The role of PTPRO in regulating glomerular pressure and
permselectivity was previously demonstrated by the
phenotype of the knockout model and antibody treatment
studies.14,15 PTPRO primers (Table S1) were designed ac-
cording to the NCBI genomic reference sequence along
contig NC_000012.11 (National Center for Biotechnology
Information [NCBI] RefSeq accession numbers
NM_030667.1 [for the mRNA] and NP_109592.1 [for the
protein]). The entire coding region and the exon-intron
boundaries of PTPRO were sequenced directly from frag-
ments amplified by PCR with an Applied Biosystems
3130 genetic analyzer according to the manufacturer’s
protocol.
In the present study, a homozygous c.2627þ1G>T
(p.Glu854_Trp876del) donor splice-site mutation in
PTPRO in family A (in which both parents were heterozy-
gous) was observed (Figures 1C–1F and Table 1).
In this family, the index individual (Figure 1A, IV-1) pre-
sented with SRNS at age 9. He was treated with prednisone
and cyclophosphamide without effect. A partial reduction
of proteinuria was noted in response to combined therapy
with cyclosporin A, methylprednisolone pulses, enalapril,
and losartan (Table 1). The second affected sibling
(Figure 1A, IV-2) was diagnosed at age 5. Although cyclo-
phosphamide and cyclosporin A failed to induce remis-
sion, a partial response to combined pulse methylprednis-
olone and cyclosporin A therapy was observed (Table 1).
We expanded this study to include other individuals
with the identical phenotype in order to identify addi-
tional families. Screening for a highly polymorphic intra-
genic DNA marker (D12S1303) in 120 Turkish and 13
non-Turkish individuals in the PodoNet registry for homo-
zygosity yielded 17 candidate families for direct
sequencing. DNA-sequencing analysis identified a second
Turkish family (family B) with a distinct homozygous
c.2745þ1G>A (p.Asn888Lysfs*3) donor splice-site muta-
tion in PTPRO (Figures 2A–2E and Table 1). This family
included three affected siblings and one healthy sibling;
the parents were heterozygous, and the healthy sibling
did not carry themutation (Figures 2B and 2C and Table 1).
The first sibling in family B (Figure 2A, IV-1) presented
with SRNS at age 14; cyclophosphamide, pulsemethylpred-
nisolone, and cyclosporin A failed to induce remission.
Renal function progressively deteriorated and ESKD
occurred at age 18. She received a living-related kidney
transplant, and therewasnodisease recurrence. This sibling
also carried a heterozygous p.Arg229Gln (c.686G>A) varia-
tion in the podocin. The second and third siblings
(Figure 2A, IV-2 and IV-3) were diagnosed by family
screening while they were clinically asymptomatic after
screening for proteinuria because of family history. The
second sibling (Figure 2A, IV-2) was resistant to oral steroid
treatment; however, partial remission with intensified
immunosuppression and a renin-angiotensin system
blockade (i.e., oral and pulse steroid, cyclophosphamide,The American Journal of Human Genetics 89, 139–147, July 15, 2011 141
Figure 2. Identification of Family B with
a Different PTPROMutation than Family A
(A) Pedigree of the second family. Squares
indicatemales and circles indicate females.
Solid symbols indicate affected individ-
uals. Double-horizontal bars indicate
consanguinity. P indicates the proband.
(B–D) Sequence electropherograms of
exon 19 of PTPRO. The wild-type sequence
in both healthy offspring in the family and
a healthy control (B, arrow). Whereas the
unaffected parents were heterozygous for
the mutation (C, arrow), all affected
siblings had a homozygous donor splice-
site c.2745þ1G>A (p.Asn888Lysfs*3)
mutation (D, arrow). Dashed blue lines
show exon-intron boundaries.
(E) Position of the mutation is shown as
red in the genomic sequence. Horizontal
arrows indicate subsequent introns and
exons. Vertical arrows show intron-exon
boundaries. Four-digit numbers show
starting and ending nucleotides of the
respective exons.
(F) Sequencing of PTPRO cDNA of both
peripheral blood lymphocytes from
healthy individuals and nephrectomy
specimens showed that exon 18 was fol-
lowed by exon 19 (normal splicing).
(G–I) NM_002848.2: c.2745þ1G>A donor
splice-site mutation results in skipping of
evolutionary conserved exon 19, which
introduces a premature stop codon at the
very beginning of exon 20. Dashed line
shows exon-exon boundaries. Organiza-
tion of exons and respective domains in
variant 2 of PTPRO is schematically shown
(H and I). The following abbreviations are
used: SP, signal peptide; FN, fibronectin
type III; TMD, transmembrane domain;
TPPD, tyrosine protein phosphatase
domain.
(J) Allelic expression analysis of wild-type
and mutant transcripts of PTPRO in
a healthy sibling (IV-4), a heterozygous
parent (III-2), and an affected individual
(IV-2). According to comparative quantifi-
cation analysis, the mutant transcript was
decreased nearly 30-fold in cDNA samples
from both a heterozygous parent and the
affected individual (wt: wild-type allele,
m: mutant allele).cyclosporin A, enalapril, and losartan) was achieved. The
third sibling (Figure 2A, IV-3) initially achieved complete
remission with oral prednisone treatment but then
developed a steroid-dependent clinical course. A course
of oral cyclophosphamide and a maintenance course
of low-dose alternate-day oral steroids yielded remission142 The American Journal of Human Genetics 89, 139–147, July 15, 2011for 1 year. Subsequently, this indi-
vidual experienced another relapse,
which was completely resistant to
oral steroids but partially responsive
to monthly intravenous steroid
pulses. At the time this report waswritten, when the siblings were ages 15 and 12, their
glomerular filtration rate was normal; however, they
both had proteinuria. The study protocol was approved
by the Hacettepe University Ethics Committee (TBK08/
1-57). Participants or their guardians provided written
informed consent.
Figure 3. Restriction Fragment Length Polymorphism Analysis Visualized with Ethidium-Bromide Staining after Agarose Gel Electro-
phoresis
Lane 1 shows sizemarker with corresponding bands as base pairs. Lanes 2–5 show BsrI digestion in Family Awith fragments of 182 bp for
the mutated allele, and 116 and 66 bp, respectively, for the normal allele. Lanes 2 and 3 show heterozygous parents (III-1 and III-2,
respectively, in Figure 1). Lanes 4 and 5 belong to affected siblings (IV-1 and IV2, respectively, in Figure 1A). Healthy control (as shown
in lane 6) shows 2 bands (116 and 66 bp, respectively). Lanes 7-13 show HphI digestion in Family B with fragments of 294 bp for the
mutated allele and 214 and 66 bp, respectively, for the normal allele. Lanes 7 and 8 depict heterozygous parents (III-1 and III-2, respec-
tively, in Figure 2A) with three bands (294, 214, and 66 bp). Homozygous siblings (IV-1, IV-2, and IV-3 in Figure 2A), as shown in lanes 9,
10, and 11, give one band with 294 bp. Lanes 12 and 13 correspond to a healthy sibling (IV-4 in Figure 2A) and a healthy control, respec-
tively, and are associated with two bands of 214 and 66 bp.PTPRO extends over 51 kb and contains 26 exons. This
geneencodes the receptor-typeproteintyrosinephosphatase
that contains a single intracellular catalytic domain with
a characteristic signature motif. The gene product is an inte-
gral membrane protein. Several alternatively spliced tran-
script variants that exhibit tissue-specific expression have
been described; among them, only variants 1 and 2 are ex-
pressed in theglomerulus.Variant1 (NM_030667.1) encodes
the longest isoform. The encoded protein has a large extra-
cellular domain containing eight repeats of a fibronectin-
type-III-like motif. Variant 2 (NM_002848.2) lacks exon 17,
resulting in a missing juxtamembrane region (Figure S2).
We analyzed the effects of the identified mutations on
RNA splicing in both families.
We first predicted the consequences of the mutations via
in silico analysis by using automated splice-site analysis
software.16,17 For the c.2745þ1G>Amutation the software
predicted an abolished site, whereas for the c.2627þ1G>T
mutation a leaky site was predicted. We then used cDNA
analysis to observe these changes. We collected fresh hepa-
rinized blood from all the individuals, their parents, and
healthy controls. In addition, a kidney biopsy was per-
formed in one affected individual from each family
(Figure 1A, IV-2, and Figure 2A, IV-2).
RNA was obtained from lymphocytes of affected indi-
vidual and controls with the QIAGEN RNeasy Mini Kit
and from kidney biopsy specimens as well as nephrectom-
ized kidney tissues removed for unrelated causes with
TRIzol reagent (Invitrogen) according to the manufac-
turer’s recommendations. cDNA was generated by reverse
transcription with the QIAGEN QuantiTect Reverse Tran-
scription Kit. After cDNA synthesis, PTPRO transcripts
were amplified with gene-specific primers (see Table S1),
and then PCR products were sequenced.
Expression of variant 2 (NM_002848.2) was observed in
both lymphocytes and kidney tissues. The results unequiv-The Amocally showed the skipping of exon 16 in family A (Figures
1G–1I) and of exon 19 in family B (Figures 2F–2H) in both
lymphocyte and kidney tissue cDNA in all the affected
individuals.
In family A, the skipped exon resulted in a protein that
lacked 23 amino acids (p.Glu854_Trp876del) (Figure 1J).
These amino acids are not within a recognizable domain
ormotif of the protein; however, they are highly conserved
in PTPRO orthologs in evolutionarily distant organisms
such as Danio rerio and Fugu rubripes, suggesting a con-
served function of the domain assembly within PTPRO
(Figure 1J and Figure S3). In family B, the skipped exon
introduced a premature stop codon at the very beginning
of exon 20 (Figure 2G). This change could lead to a protein
lacking the tyrosine protein phosphatase domain and the
substrate-binding regions (Figure 2I) or nonsense-medi-
ated decay of mRNA. Thus, we further analyzed allelic
expression of wild-type and mutant PTPRO alleles in
lymphocyte RNA samples from a heterozygous parent (Fig-
ure 2A, III-2), a healthy sibling (Figure 2A, IV-4), and an
affected individual (Figure 2A, IV-2). Quantitative real-
time PCR analysis showed a dramatic decrease in the
mutant allele compared to the wild-type allele, suggesting
that mRNA was degraded by nonsense-mediated decay
(Figure 2J).
Because both families carrying PTPROmutations were of
Turkish origin, we excluded the presence of both muta-
tions in 180 healthy Turkish controls by using an indepen-
dent method—restriction fragment length polymorphism
analysis (RFLP) (Figure 3). Using genomic DNA from family
members, we assessed the presence of G/T donor splice-
site mutations in intron 16 via amplification by PCR
followed by BsrI digestion, and we assessed the presence
of G/A donor splice-site mutations in intron 19 via
amplification by PCR followed by HphI restriction diges-
tion. We visualized 182 bp fragments for the mutatederican Journal of Human Genetics 89, 139–147, July 15, 2011 143
Figure 4. Histopathological Assessment
of the Kidney Biopsies
(A and B) Light microscopy, (C and D)
immunohistochemical, and (E and F) elec-
tron microscopy findings in biopsied
affected individuals from families A and
B are shown. The first and second columns
are related to individual IV-2 in family A
and individual IV-2 in family B, respec-
tively. (A) One of the segmentally scle-
rosed glomeruli. The sclerosed segment
is depicted by an asterisk (hematoxylin
and eosin staining [H&E], 5003). (C)
Podocytes showed strong staining with
monoclonal antibody against PTPRO
(immunohistochemistry, anti-GLEPP1 Ab,
5003). (E) Generalized foot process fusion
(arrows) and widespread thinning of
glomerular basement membranes, with
smooth outer and inner contours (electron
microscopy, lead citrate and uranyl acetate
staining, 150003). Bar indicates 1 mm. (B)
Essentially normal glomeruli with open
capillary lumina light microscopically
(H&E, 1003). (D) Complete lack of PTPRO
(immunohistochemistry, anti-GLEPP1 Ab,
1003). (F) Diffuse foot process effacement
(arrows) and extensive microvillus trans-
formation of podocytes (electron micros-
copy, lead citrate and uranyl acetate stain-
ing, 80003). The scale bar indicates 2 mm.allele, and 116 and 66 bp fragments for the normal allele
for BsrI digestion by using agarose gel electrophoresis.
HphI digestion generated fragments of 294 bp for the
mutated allele and 214, 66, and 14 bp for the normal allele;
the expected fragments, except for 14 bp, were visualized.
In addition, 15 individuals whowere from the SRNS cohort
from the Mario Negri Institute in Bergamo, Italy, and
whose SNRS was unexplained were independently
sequenced, and no mutations were identified.
Kidney biopsies from each family were treated accord-
ing to standard methods. For immunohistochemical anal-
ysis, antibody against PTPRO (anti-GLEPP1 5C11, BioGe-
nex catalog number MU336-UC) at a dilution of 1:50 in144 The American Journal of Human Genetics 89, 139–147, July 15, 2011antibody diluents buffer (ScyTek
ABB125) was used. Specific immuno-
peroxidase staining was developed
with the ScyTek UltraTek HRPAntipo-
lyvalent Staining System (AMF080
horseradish peroxidase and goat
3,30-diaminobenzidine kit, ScyTek)
with 3,30-diaminobenzidine (DAB)
as the chromogen. DAB-stained slides
were counterstained with hematox-
ylin. The kidney biopsy specimen of
the second sibling in family A
(Figure 1A, IV-2) showed two globally
and three segmentally sclerosed
glomeruli (among the 25 glomeruli
retrieved) located in the juxtamedul-lary cortex (Figure 4A). Adhesion between Bowman
capsules and capillary tufts was noted in another glomer-
ulus. Cellular proliferation and matrix expansion were not
observed, whereas mild focal tubulointerstitial fibrosis and
atrophy was noted. Immunofluorescence analysis showed
weak to moderate perimesangial and rare mesangial IgM
but no other immunoglobulin or complement deposition.
Immunohistochemical analysis with a monoclonal anti-
body against PTPRO showed diffuse and strong staining
in the podocytes, and this staining was similar to that
observed in control kidney tissue (Figure 4C). Electron
microscopy showed diffuse foot process effacement and
widespread attenuation of the glomerular basement
membranes (<150 nm), which were thought to be consti-
tutional because of the absence of hematuria. The outer
and inner contours of the basement membrane were
smooth and without signs of irregular thickening, lamella-
tion, or splitting. Podocytes appeared swollen and vacuo-
lated. Immune-type dense deposits were not present.
Endothelial cells showed slight swelling and vacuolization
(Figure 4E). The disease was diagnosed as focal segmental
glomerulosclerosis. A kidney biopsy of the second sibling
in family B (Figure 2A, IV-2) showed that of the 38
glomeruli, three were globally sclerosed; the remaining
glomeruli were normal or showed slight mesangial
prominence without hypercellularity or segmental scle-
rosis. The tubulointerstitial compartment was unremark-
able except for narrow zones of interstitial fibrosis and
tubular atrophy around the globally sclerosed glomeruli
(Figure 4B). Immunofluorescence showed that there was
not any immunoglobulin or complement deposition. In
contrast to family A, immunohistochemical analysis in
family B did not show immunostaining with monoclonal
antibody against PTPRO in podocytes (Figure 4D). Elec-
tron microscopy showed diffuse foot process fusion and
extensive microvillus transformation of the podocytes
(Figure 4F). The pathological diagnosis was minimal
change disease.
PTPRO is a tyrosine phosphatase expressed at the apical
membrane of the podocyte foot processes. Tyrosine phos-
phorylation of tight junction proteins plays a major role
in controlling paracellular permeability, cell signaling,
and actin cytoskeleton remodeling. Tyrosine phosphory-
lation of nephrin and ZO-1, key components of the slit
diaphragm, alters their association with other slit pore
proteins in the membrane.18,19 Abolished PTPRO expres-
sion has been observed in various proteinuric nephropa-
thies, such as primary focal segmental glomerulosclerosis
and severe IgA nephropathy, as well as in experimental
podocyte damage leading to foot process efface-
ment.20–22 In puromycin aminonucleoside (PAN)
nephropathy, PTPro downregulation preceded the onset
of proteinuria.22 The blockade of PTPro by specific anti-
bodies increased albumin permeability in isolated rat
and rabbit glomeruli, further supporting the essential
role of this protein in maintaining glomerular permselec-
tivity.15 In the present study, we observed that both muta-
tions caused aberrant RNA splicing; in one case it led to
a premature stop codon (p.Asn888Lysfs*3) and degrada-
tion of the mRNA via nonsense-mediated decay and in
another case to a protein lacking 23 amino acids
(p.Glu854_Trp876del). Whereas nonsense-mediated decay
of the mRNA resulting from the skipped exon 19 caused
complete deficiency of the immunoreactive protein, the
expression, and membrane location of the shortened
protein resulting from skipped transcription of exon 16
appeared to be preserved. We think that the latter muta-
tion might still be functionally relevant because the 23
missing amino acids constitute an evolutionarily highly
preserved region of the protein.The AmIn the present study, histopathological findings in one
member of each family showed relatively mild lesions
and focal segmental or global sclerosis of a small frac-
tion of glomeruli. Ultrastructural analysis showed that
the profound foot process effacement and altered
phenotypic appearance of the podocytes resembled the
anomalies observed in Ptpro/ mice.14 Ptpro-deficient
podocytes exhibit an amoeboid shape with blunted
and widened foot processes rather than the typical octo-
poid shape, despite the normal glomerular structure
observed with light microscopy.14 Although Ptpro/
mice have shortened foot processes and a reduced total
slit diaphragm length, they do not appear to develop
major proteinuria. This apparent discrepancy with the
increased albumin permeability induced by blocking
PTPro activity in rat and rabbit glomeruli15 and with
the nephrotic state observed in children with geneti-
cally altered PTPRO might be due to organism-specific
differences in functional redundancy by other phospha-
tases.
Notably, four of the five affected children in the present
study were partially responsive to intensified immunosup-
pressive treatment. In keeping with this observation,
steroid treatment selectively attenuated downregulation
of PTPro in the PAN model.22 Regulation of phosphatases
is an important mechanism of glucocorticoid action in
many biological systems;23 hence, PTPRO mutations may
represent another hereditary disorder of podocyte function
with partial susceptibility to immunosuppressive therapy,
as previously observed in individuals with abnormalities
in phospholipase C epsilon-1, another protein involved
in podocyte cell signaling.8
The oldest sibling in family B (Figure 2A, IV-1) had
a more severe disease course than the other affected
siblings and had complete resistance to intensified immu-
nosuppressive therapy and progressed to ESKD. Of note,
the p.Arg229Gln polymorphism in the gene encoding
podocin—the most commonly mutated protein in child-
hood-onset SRNS—was observed in this individual but
not in the other siblings. p.Arg229Gln, which is the most
frequent podocin variant and which occurs in 3%–13%
of Europeans, is considered a nonneutral polymorphism,
because the mutant protein exhibits decreased nephrin
binding in vitro.24 Late-onset SRNS has been described in
individuals compound heterozygous for the p.Arg229Gln
variant together with a pathogenic NPHS2 mutation.25
An interesting possibility is that heterozygosity for podo-
cin p.Arg229Gln modified the onset and course of the
disease in family B.
In conclusion, we identified recessive mutations in
PTPRO as another cause of childhood nephrotic syndrome
with reduced steroid responsiveness and therefore propose
use of the denomination NPHS6 as a synonym. While ex-
panding the spectrum of hereditary nephrotic syndromes,
PTPRO will also provide a better understanding of the
pathogenetic mechanisms underlying proteinuric diseases
and the clinical management of nephrotic children.erican Journal of Human Genetics 89, 139–147, July 15, 2011 145
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